HIV-1 has evolved multiple mechanisms to elude immune control. The view of virus as classifiable into distinct subtypes needs to reflect the reality of the constant emergence of new strains. This review discusses the implications of subtype diversity in HIV-1 for possible differential rates of disease progression, responses to antiretroviral therapy (including the development of resistance), and vaccine development.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: